...
首页> 外文期刊>Cardiovascular engineering and technology >Regenerative Stem Cell Therapy Optimization via Tissue Engineering in Heart Failure with Reduced Ejection Fraction
【24h】

Regenerative Stem Cell Therapy Optimization via Tissue Engineering in Heart Failure with Reduced Ejection Fraction

机译:通过组织工程在心力衰竭中通过减少射血分数的再生干细胞疗法优化

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The prevalence of heart failure (HF) is continuously rising in both the industrialized and non-industrialized nations. Despite current therapeutic advances, prognosis of HF patients remains poor. Presently, therapeutic pharmacological and device strategies for HF with reduced ejection fraction (HFrEF) are mostly palliative and do not induce regeneration of lost myocardial tissue. Stem cell therapy has demonstrated promising results in clinical studies by promoting myocardial restoration in HFrEF subjects. Despite decades of investigation, many challenges remain unanswered to the widespread clinical application of stem cell therapy for HFrEF. This review will describe the foundational work already accomplished in cardiac stem cell therapy, advantages and limitations of the various candidates for tissue restoration, their presumed mechanisms of action, the role of scaffolding materials as well as the challenges that exist for widespread clinical application.
机译:在工业化国家和非工业化国家,心力衰竭(HF)的患病率都在不断上升。尽管目前的治疗进展,心衰患者的预后仍然很差。目前,射血分数降低的心力衰竭(HFrEF)的治疗药理学和设备策略大多是姑息性的,不会诱导丢失的心肌组织再生。通过促进HFrEF受试者的心肌恢复,干细胞疗法在临床研究中已显示出有希望的结果。尽管进行了几十年的研究,但干细胞疗法在HFrEF临床上的广泛应用仍面临许多挑战。这篇综述将描述在心脏干细胞治疗方面已经完成的基础性工作、各种组织修复候选物的优势和局限性、它们假定的作用机制、支架材料的作用以及广泛临床应用中存在的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号